Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration
START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia (TD), including utilization and patient satisfactionAUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year long-term data1,2 approved for adults with TD and...
Source: pharmiweb.com
